Liver Transplant in India and UAE | Complete Patient Guide

• ELIGIBLE CONDITIONS: End-stage liver disease (MELD score ≥15 or Child-Pugh Class C), acute fulminant hepatic failure (acetaminophen toxicity, viral hepatitis, drug-induced liver injury), hepatocellular carcinoma within Milan Criteria (single nodule ≤5 cm, or up to 3 nodules none exceeding 3 cm, no macrovascular invasion, no extrahepatic spread), metabolic liver diseases (Wilson's disease, Alpha-1 antitrypsin deficiency, hereditary hemochromatosis, glycogen storage disorders), cholestatic liver diseases (PBC, PSC) with MELD ≥12 and refractory symptoms, polycystic liver disease with massive hepatomegaly, and Budd-Chiari syndrome refractory to anticoagulation/TIPS.

• REQUIRED PRE-TRANSPLANT DIAGNOSTICS: Liver function panel (ALT, AST, ALP, GGT, bilirubin, albumin, PT/INR), MELD-Na score calculation, complete metabolic panel and CBC with differential, serologies (HBsAg, HBcAb, HCV-RNA quantitative PCR, HIV-1/2, CMV IgG/IgM, EBV, HSV, VZV), cross-sectional imaging (triple-phase MDCT or gadoxetate-enhanced MRI liver for anatomy and tumor staging), Doppler ultrasound of portal and hepatic vasculature, upper GI endoscopy (variceal grading), cardiac evaluation (transthoracic echocardiography, stress testing, right-heart catheterization if portopulmonary hypertension suspected), pulmonary function tests and CT chest, renal function (GFR estimation, 24-hour urine protein), bone mineral density (DEXA scan), nutritional assessment (MUST/NRS-2002 scoring), and psychosocial/addiction counseling clearance.

• FOR LIVING DONOR CANDIDATES: ABO compatibility testing, volumetric CT hepatic assessment (right lobe graft volume ≥40% of total liver volume preferred; residual donor left lobe ≥30%), liver biopsy if steatosis >10% on imaging, donor MELD risk stratification, laparoscopic donor hepatectomy suitability assessment.

• ABSOLUTE CONTRAINDICATIONS: Extrahepatic malignancy (except fully resected non-melanoma skin cancer with ≥2-year disease-free interval), active systemic sepsis or uncontrolled infection, severe irreversible cardiopulmonary disease (mean PAP >50 mmHg, FEV1 <50% predicted unresponsive to bronchodilators), active alcohol or illicit substance use without sustained sobriety (typically ≥6 months required), anatomical barriers precluding surgical reconstruction, and documented non-adherence to medical therapy without psychosocial mitigation plan.

• RELATIVE CONTRAINDICATIONS: Age >70 (evaluated case-by-case), significant obesity (BMI >40), prior complex hepatobiliary surgery, HIV infection with AIDS-defining illness, and severe sarcopenia requiring prehabilitation.

DECEASED-DONOR ORTHOTOPIC LIVER TRANSPLANTATION (DDOLT): The gold-standard procedure using a whole-organ graft from a brain-dead (DBD) or donation-after-circulatory-death (DCD) donor. The piggyback (caval-sparing) technique — preferred at most high-volume centers — preserves the native retrohepatic IVC, allowing partial side-clamping rather than full caval occlusion, reducing hemodynamic instability and venovenous bypass requirement. Biliary reconstruction is performed as duct-to-duct choledochocholedochostomy over a T-tube or internal stent, or Roux-en-Y hepaticojejunostomy in recipients with PSC, biliary atresia, or significant size mismatch. Intraoperative cell salvage and thromboelastography (TEG/ROTEM)-guided transfusion protocols are standard at partner centers to minimize allogeneic blood product use.

LIVING-DONOR LIVER TRANSPLANTATION (LDLT): The dominant modality in India and increasingly common in the UAE due to limited deceased-donor registries. The donor undergoes right hepatectomy (segments V–VIII, ~55–65% of liver volume) or, for pediatric recipients, left lateral sectionectomy (segments II–III). The donor operation has evolved to include laparoscopic-assisted or total laparoscopic donor hepatectomy at specialized centers, reducing donor morbidity, blood loss, and recovery time compared to open hepatectomy. LDLT eliminates cold ischemia time concerns, allows elective scheduling, and affords the transplant team optimal graft quality assessment. Small-for-size syndrome (SFSS) — defined as graft-to-recipient body weight ratio (GRWR) <0.8% — is mitigated through portal pressure modulation strategies including splenic artery ligation, splenectomy, or portocaval shunting.

SPLIT-LIVER TRANSPLANTATION: A single deceased-donor liver is surgically divided (ex-situ or in-situ) into two functional grafts — typically a left lateral segment (II–III) for a pediatric recipient and an extended right lobe for an adult — maximizing organ utilization. This technique requires advanced hepatobiliary surgical expertise and is offered at select high-volume Indian centers (e.g., ILBS New Delhi, Medanta, Apollo).

LAPAROSCOPIC / ROBOTIC-ASSISTED DONOR HEPATECTOMY: Total laparoscopic right donor hepatectomy (TLRDH) and robot-assisted donor hepatectomy (using the Da Vinci Xi surgical system) represent the frontier of minimally invasive liver surgery. Robotic platforms provide 3D magnification, enhanced dexterity in confined spaces, and tremor filtration — particularly advantageous for precise hilar dissection and hepatic vein control. Centers such as Medanta–The Medicity and King's College Hospital Dubai offer robotic donor hepatectomy, with published donor complication rates <5% and zero mortality in experienced hands.

MACHINE PERFUSION FOR DECEASED-DONOR GRAFTS: Normothermic machine perfusion (NMP, e.g., OrganOx metra device) and hypothermic oxygenated machine perfusion (HOPE) are being adopted at select centers to rehabilitate marginal DCD grafts, reduce ischemia-reperfusion injury, and allow ex-vivo graft viability assessment before implantation — expanding the donor pool for recipients awaiting deceased-donor organs.

HEPATOCELLULAR CARCINOMA (HCC) PROTOCOL TRANSPLANTATION: Patients with HCC within Milan Criteria (or expanded UCSF Criteria) undergo bridging or downstaging therapies prior to transplant: transarterial chemoembolization (TACE), transarterial radioembolization with Yttrium-90 microspheres (TARE/SIRT), stereotactic body radiotherapy (SBRT), or thermal ablation (microwave or radiofrequency). Post-transplant, mTOR inhibitor-based immunosuppression (everolimus) is preferred for its antiproliferative properties, with 5-year HCC recurrence rates below 15% in Milan-Criteria patients at top programs.

PEDIATRIC LIVER TRANSPLANTATION: Biliary atresia is the leading indication. Living-donor left lateral segment grafts are standard. Roux-en-Y hepaticojejunostomy is the universal biliary reconstruction. Pediatric-specific immunosuppression dosing (tacrolimus 0.15–0.30 mg/kg/day in two divided doses, targeting higher initial troughs of 10–15 ng/mL) and dedicated pediatric hepatology follow-up are essential components offered at Apollo, Fortis, and NMC Specialty Hospital programs.

PHASE 1 — REMOTE PRE-EVALUATION (Weeks 1–3, from home country): Patient submits medical records to GAF Healthcare coordinators. Transplant hepatologist and surgeon review records remotely and provide a written opinion within 48–72 hours. If suitable, a detailed investigation protocol is issued. Blood group typing, HLA typing, crossmatch panels, and initial serologies are performed locally. Imaging (MRI liver, CT chest/abdomen) is reviewed by destination center radiologists. Psychosocial evaluation and addiction medicine clearance is initiated. For LDLT, potential living donors undergo preliminary health screening remotely.

PHASE 2 — ARRIVAL & IN-PERSON EVALUATION (Days 1–7 in India or UAE): GAF Healthcare arranges airport pickup, dedicated interpreter, and accommodation for patient and attendant. Patient is admitted or seen as outpatient for comprehensive workup: repeat LFTs, MELD-Na calculation, Doppler ultrasound, echocardiography, pulmonary function tests, upper GI endoscopy, DEXA scan, nutritional assessment, and anesthesia pre-assessment. Living donor undergoes full evaluation including CT volumetry and liver biopsy (if indicated) simultaneously. Multidisciplinary transplant board (hepatologist, transplant surgeon, anesthesiologist, infectious disease specialist, nephrologist, cardiologist, dietitian, transplant coordinator, social worker) convenes to grant transplant listing approval.

PHASE 3 — TRANSPLANT LISTING & WAITING (Variable: Days to Weeks): For LDLT, once donor clearance is granted, surgery is scheduled within 1–2 weeks. For DDLT, patient is listed with the regional/national organ procurement organization (NOTTO in India; Dubai Health Authority allocation system in the UAE). High MELD score patients receive priority. Median wait time for international patients using living donors is 2–4 weeks from arrival to surgery.

PHASE 4 — PRE-OPERATIVE PREPARATION (Days –3 to 0): Antibiotic bowel preparation, nutritional optimization (branched-chain amino acid supplementation), prophylactic antifungal coverage (fluconazole), antiviral prophylaxis for CMV-seropositive recipients (valganciclovir), HBV-positive recipients receive hepatitis B immunoglobulin (HBIG) and antiviral therapy (entecavir or tenofovir) continuation. Anesthesia team places arterial line, large-bore central venous access, and pulmonary artery catheter. Thromboelastography baseline is obtained. Operative duration is planned for 8–12 hours.

PHASE 5 — THE SURGERY: Recipient hepatectomy (2–4 hours): Mobilization and removal of the diseased liver, control of hepatic vessels and bile duct. Anhepatic phase (45–90 minutes): Vascular anastomoses constructed (suprahepatic caval/hepatic vein, portal vein), graft flushed and reperfused. Arterial reconstruction: Hepatic artery anastomosis under microscopic loupe magnification. Biliary reconstruction: Duct-to-duct or Roux-en-Y. Drain placement. Intraoperative vasopressor management, TEG-guided transfusion, and continuous hemodynamic monitoring are standard throughout.

PHASE 6 — ICU RECOVERY (Days 1–10 post-op): Patient extubated within 12–24 hours when hemodynamically stable. Daily liver function monitoring (AST, ALT, bilirubin, PT/INR, lactate). Tacrolimus initiated at Day 1–2, mycophenolate mofetil at Day 2–3, steroid taper begun. Doppler ultrasound at 24 hours to confirm hepatic artery, portal vein, and hepatic vein patency. Drain output, bile output, and wound assessment daily. Early mobilization protocol initiated by physiotherapy team from Day 2. Renal function monitored vigilantly; dose-adjusted tacrolimus or switch to mTOR inhibitor if significant nephrotoxicity develops.

PHASE 7 — STEP-DOWN WARD & REHABILITATION (Days 10–28 post-op): Transfer from ICU when vasopressor-free, spontaneously breathing on room air, and LFTs trending toward normalization. Oral diet reintroduction with dietitian guidance; high-protein, low-sodium diet. Liver function nadir typically reached by Day 7–10; progressive improvement expected by Week 3. Immunosuppression monitoring (tacrolimus trough every 2–3 days), CMV/EBV surveillance PCR at Week 2 and 4. Liver biopsy performed if biochemical rejection pattern detected (rising bilirubin + transaminases + eosinophilia) — treated with IV methylprednisolone pulse (500–1,000 mg × 3 days). Discharge criteria: stable LFTs, oral tacrolimus therapeutic, ambulating independently, tolerating full oral diet.

PHASE 8 — OUTPATIENT FOLLOW-UP IN DESTINATION COUNTRY (Weeks 4–12): Weekly outpatient clinic visits with transplant hepatologist. LFTs, tacrolimus trough, CBC, renal panel twice weekly for Month 1, then weekly for Month 2. Wound assessment and drain site healing. PCP prophylaxis (trimethoprim-sulfamethoxazole) continued for 6–12 months. Antifungal (fluconazole) for 3 months. CMV prophylaxis (valganciclovir 900 mg daily) for 3–6 months in high-risk recipients. Bone health management (calcium + vitamin D supplementation, bisphosphonate therapy if osteoporosis). Fit-to-fly assessment: minimum 8–10 weeks post-transplant for long-haul flights (>6 hours); patient must be ambulatory, normoglycemic, on stable tacrolimus dose with therapeutic troughs, and free of active infection or rejection episodes. GAF Healthcare issues a medical summary and connects patient with a local hepatologist for home-country surveillance.